¿Cómo se comparó el EPS reciente de UTRS con las expectativas?
¿Cómo fue el desempeño de los ingresos de Minerva Surgical Inc UTRS en el último trimestre?
¿Cuál es la estimación de ingresos para Minerva Surgical Inc?
¿Cuál es la puntuación de calidad de ganancias de Minerva Surgical Inc?
¿Cuándo informa Minerva Surgical Inc sus ganancias?
¿Cuáles son las ganancias esperadas de Minerva Surgical Inc?
¿Superó Minerva Surgical Inc las expectativas de ganancias?
Estadísticas clave
Cierre Anterior
$0.0002
Precio de apertura
$0.0001
Rango del día
$0.0001 - $0.0002
Rango de 52 semanas
$0 - $0.001
Volumen
500
Volumen promedio
750
EPS (TTM)
-8.36
Rendimiento de dividendos
--
Cap. de mercado
$1.7K
¿Qué es UTRS?
Minerva Surgical, Inc. engages in the research, development, manufacture, and commercialization of invasive solutions for uterine healthcare needs of women. The company is headquartered in Santa Clara, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. The firm designs, manufactures, distributes, and commercializes a suite of products that offer effective alternatives to hysterectomy, with a focus on diagnosing and treating the underlying causes of Abnormal Uterine Bleeding (AUB). Its solutions are designed for use across a variety of care settings and focused on improving clinical outcomes and preserve uterine anatomy. The company delivers devices that treat the root causes of AUB in both the normal and irregular shaped uterus. The firm's products include Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Operative Hysteroscopy System (Symphion), Resectr Tissue Resection Device (Resectr), and HERizon Disposable Hysteroscope. Its Minerva EAS includes PlasmaSense Technology, which monitors uterine cavity. The company also provides HERizon Hysto-Kit, which supports in-office hysteroscopy.